My understanding is that the IP belongs to QUT that is why we pay exorbitant quarterly fees to QUT fore "research" the results of which we have never heard. TIS merely has a licence which QUT can terminate in the event of any change of control of TIS except where the SP is above a pre-defined figure (which I would expect we are no where near). As far as QUT and directors and management are concerned as long as shareholders keep fronting up the CR to keep them going, they are sweet....
Going back to the announcement this morning I was struck by what little guidance it gives. We really know nothing about what the issue is, what it will take to fix it and how long it will take. The fact that they said they will be concentrating on the FDA suggests that it may be a while.....Really, how is that an exercise in keeping faith with shareholders and keeping us informed? How is it keeping the market properly informed?
TIS Price at posting:
11.0¢ Sentiment: None Disclosure: Held
